Stay updated on ICT-107 Immunotherapy in GBM Clinical Trial
Sign up to get notified when there's something new on the ICT-107 Immunotherapy in GBM Clinical Trial page.

Latest updates to the ICT-107 Immunotherapy in GBM Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedFooter revision updated from v3.6.3 to v3.6.4. This signals a minor frontend build update with no changes to the study details presented.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page footer revision label was updated from v3.6.2 to v3.6.3, indicating a minor template or CMS update that does not change study details or user-facing content.SummaryDifference0.0%

- Check37 days agoChange DetectedThe page revision tag was updated from v3.6.0 to v3.6.2, signaling a newer version of the page without altering the main study information.SummaryDifference0.0%

- Check51 days agoChange DetectedNew help and navigation sections were added, including How to Read a Study Record, Common Questions, and How to Join a Study, and the recruitment status now states no longer looking for participants. The label formatting for Intervention/Treatment was standardized (replacing Intervention / Treatment), and the revision tag advanced to Revision: v3.6.0.SummaryDifference0.4%

- Check58 days agoChange DetectedThe page footer now shows Revision: v3.5.5 instead of Revision: v3.5.4. This indicates a new page build or release, reflecting a maintenance update rather than a change to study content.SummaryDifference0.0%

- Check80 days agoChange DetectedThe page revision history now shows Revision: v3.5.4, replacing Revision: v3.5.3. This update indicates a new version of the study record without changing its substantive details.SummaryDifference0.0%

Stay in the know with updates to ICT-107 Immunotherapy in GBM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ICT-107 Immunotherapy in GBM Clinical Trial page.